Short Interest in Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Drops By 6.9%

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) was the target of a large decrease in short interest in the month of October. As of October 31st, there was short interest totalling 10,800 shares, a decrease of 6.9% from the October 15th total of 11,600 shares. Approximately 0.1% of the shares of the stock are short sold. Based on an average daily trading volume, of 8,500 shares, the days-to-cover ratio is currently 1.3 days.

Anebulo Pharmaceuticals Stock Down 0.7 %

Shares of NASDAQ ANEB opened at $1.52 on Wednesday. Anebulo Pharmaceuticals has a 52-week low of $1.46 and a 52-week high of $3.30. The company’s 50-day simple moving average is $1.89 and its 200-day simple moving average is $2.10. The firm has a market cap of $39.42 million, a price-to-earnings ratio of -5.07 and a beta of -1.00.

Anebulo Pharmaceuticals (NASDAQ:ANEB) last posted its quarterly earnings data on Wednesday, September 25th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.08. Equities research analysts anticipate that Anebulo Pharmaceuticals will post -0.52 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, Benchmark reiterated a “speculative buy” rating and set a $8.00 target price on shares of Anebulo Pharmaceuticals in a research report on Tuesday.

About Anebulo Pharmaceuticals

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.